Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daclizumab - AbbVie/Biogen

Next Previous
Drug Profile

Daclizumab - AbbVie/Biogen

Alternative Names: BIIB-019; DAC HYP; Dacliximab; Daclizumab high-yield process; Daclizumab HYP; HAT antibody; Humanised anti-Tac antibody; R35; RO 247375; SMART anti-Tac antibody; Zenapax; Zinbryta

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Biogen; Dana-Farber Cancer Institute; National Cancer Institute (USA); PDL BioPharma
  • Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antineoplastics; Antipsoriatics; Antivirals; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • Phase III Multiple sclerosis
  • Discontinued Asthma; Graft-versus-host disease; Haematological malignancies; Immune-mediated uveitis; Liver transplant rejection; Psoriasis; Tropical spastic paraparesis; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 25 Apr 2020 Efficacy data from a phase III DECIDE trial in Multiple sclerosis presented at the 72nd Annual Meeting of the American Academy of Neurology(AAN-2020)
  • 22 Nov 2018 Biogen and AbbVie terminates phaseIII trial in Multiple Sclerosis in Argentina, Australia, Brazil, Canada, Czech Republic, Denmark, England, Finland, France, Georgia, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Mexico, Moldova, Multinational, Poland, Romania, Russia, Scotland, Senegal, Serbia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, USA (NCT01797965)
  • 15 Sep 2018 Discontinued - Phase-III for Multiple sclerosis (Recurrent) in Puerto Rico (SC) (NCT02881567)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top